Solventum Corp SOLV

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived NYSE

Solventum Corporation ("Solventum," "we," "our," "us," or the "Company"), is a leading global healthcare company developing, manufacturing, and commercializing a broad portfolio of solutions that leverages deep material science, data science, and digital capabilities to address critical customer and patient needs. We constantly seek to enable the improvement of standards of care and move healthcare forward with innovation powered by insights, clinical intelligence, technology, and manufacturing expertise. Our 70+ year history of discovering and innovating advanced solutions has helped us solve our customers' toughest challenges.

Our solutions are relied on every day within the global healthcare industry to deliver higher-quality patient care, more efficient processes and workflows, and improved standards of safety and accuracy. Additionally, our products and services are present along a patient's journey through prevention, diagnosis, treatment, and recovery.

Last close 85.41 2026-10-23
Market cap $14.54B 2026-06-30 share count
52-week range 62.38 - 94.16

Valuation FY2025 figures against the last close

P/S1.7x
P/E9.6x
P/FCF—
EV/EBITDA7.0x
Dividend yield—
Diluted EPS8.88

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • International
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 4.7B (56.1%) 56% United States International, FY2025: 3.7B (43.9%) 44% International FY2024 United States, FY2024: 4.6B (55.2%) 55% International, FY2024: 3.7B (44.8%) 45% FY2023 United States, FY2023: 4.5B (54.5%) 55% International, FY2023: 3.7B (45.5%) 45%
Region FY2025FY2024FY2023
United States $4.67B $4.56B $4.47B
International $3.66B $3.69B $3.73B

As the company reported it, from the “Business Segments - Schedule of Sale by Geographic Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021
Revenue $8.32B$8.25B$8.20B$8.13B—
Gross profit $4.45B$4.59B$4.69B$4.70B—
R&D $739.0M$775.0M$758.0M$767.0M—
SG&A $3.08B$2.78B$2.30B$2.23B—
Operating income $2.18B$1.04B$1.69B$1.69B—
Pre-tax income $1.71B$605.0M$1.67B$1.69B—
Income tax $157.0M$127.0M$321.0M$349.0M—
Net income $1.56B$479.0M$1.35B$1.34B—
EPS, basic 8.942.777.797.78—
EPS, diluted 8.882.767.797.78—
Shares, diluted (wtd. avg.) 175.3M173.7M172.7M172.7M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021
Cash and equivalents $878.0M$762.0M$194.0M$61.0M$91.0M
Receivables $1.03B$1.04B$1.31B——
Inventory $1.07B$965.0M$857.0M——
Total current assets $3.86B$3.25B$2.52B——
Property, plant and equipment $1.33B$1.62B$1.46B——
Goodwill $5.70B$6.38B$6.54B$6.43B—
Other intangibles $2.59B$2.54B$2.90B——
Total assets $14.29B$14.46B$13.94B——
Accounts payable $687.0M$618.0M$477.0M——
Short-term debt $0$200.0M$0——
Total current liabilities $3.14B$2.70B$1.73B——
Long-term debt $5.04B$7.81B$0——
Total liabilities $9.24B$11.50B$2.28B——
Retained earnings $1.80B$242.0M$0——
Total equity $5.05B$2.96B$11.67B$11.74B$12.06B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021
Operating cash flow $369.0M$1.19B$1.92B$1.68B—
Depreciation and amortisation $489.0M$555.0M$561.0M$578.0M—
Stock-based compensation $161.0M$112.0M$39.0M$37.0M—
Capital expenditure $379.0M$380.0M$290.0M$251.0M—
Investing cash flow $2.80B-$380.0M-$230.0M-$253.0M—
Financing cash flow -$3.06B-$240.0M-$1.55B-$1.46B—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001964738-26-000007.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 2.5B 5B 7.5B 10B Revenue, FY2022: 8.1B Gross profit, FY2022: 4.7B Net income, FY2022: 1.3B Revenue, FY2023: 8.2B Gross profit, FY2023: 4.7B Net income, FY2023: 1.3B Revenue, FY2024: 8.3B Gross profit, FY2024: 4.6B Net income, FY2024: 479M Revenue, FY2025: 8.3B Gross profit, FY2025: 4.5B Net income, FY2025: 1.6B FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2021FY2022FY2023FY2024FY2025
Revenue — $8.13B $8.20B $8.25B $8.32B
Gross profit — $4.70B $4.69B $4.59B $4.45B
Net income — $1.34B $1.35B $479.0M $1.56B

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event Item 8.01
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%